Articles Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương 15/05/2024

20. CHANGES IN PLASMA MATRIX METALLOPROTEINASE-9 CONCENTRATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AND OUT OF EXACERBATION AT MILITARY HOSPITAL 103 IN 2023

Ta Ba Thang1,2, Nguyen Thanh Phuong3,4, Nguyen Cong Tien1,2, Dao Ngoc Bang1,2
1 Military Hospital 103
2 Bệnh viện Quân y 103
3 Viet Tiep Hospital
4 Bệnh viện Hữu nghị Việt Tiệp
Corresponding author: Bsdaongocbang@gmail.com
DOI: 10.52163/yhc.v65iCD3.1116
21 Views
9 Downloads
Abstract

Objective: To describe changes in plasma Matrix Metalloproteinase-9 concentrations in patients with chronic obstructive pulmonary disease in and out of exacerbation at 103 Military Hospital in 2023.

Subjects and methods: A case-control study on 35 COPD patients treated inpatients at the Respiratory Center, Military Hospital 103 and 30 healthy people. Quantification of plasma MMP-9 levels by using ELISA technique.

Results: There was no difference between plasma MMP-9 concentrations in COPD patients in and out of exacerbations, compared to healthy groups (p > 0.05). Plasma MMP-9 concentrations during exacerbation increased significantly in the group of patients with increased white blood cell counts (p < 0.001). Patients treated by corticosteroids before admission had lower plasma MMP-9 concentrations than the group without corticosteroids treatment (p < 0.001). Plasma MMP-9 concentrations in COPD patients after the exacerbation increased significantly in current smokers, comparing with current non-smokers (p < 0.001). After the exacerbation, patients with COPD type PP had a median plasma MMP-9 concentration of 61.2 ng/mL, significantly higher than patients with COPD type BB (p = 0.009).

Conclusions: In the exacerbation, plasma MMP-9 concentrations were higher in patients with increased white blood cell counts and lower in patients using corticosteroids. After the exacebation, plasma MMP-9 concentrations were higher than in patients who had COPD type PP and were current smokers.

References
[1]
Churg A, Zhou S et al., Series matrix metalloproteinases Google Scholar
[2]
in lung health and disease": Matrix metalloproteinases in Google Scholar
[3]
COPD, Eur Respir J, 39(1), 2012, pp. 197-209. Google Scholar
[4]
Dimic-Janjic S, Hoda MA et al., The usefulness Google Scholar
[5]
of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio Google Scholar
[6]
for diagnosis and assessment of COPD severity, Google Scholar
[7]
Eur J Med Res, 28(1), 2023, pp. 127. Google Scholar
[8]
Kang MJ, Oh YM et al., Lung matrix metalloproteinase- Google Scholar
[9]
correlates with cigarette smoking and obstruction Google Scholar
[10]
of airflow, J Korean Med Sci, 18(6), 2003, pp. 821-7. Google Scholar
[11]
Li Y, Lu Y et al., Relationships of MMP-9 and Google Scholar
[12]
TIMP-1 proteins with chronic obstructive pulmonary Google Scholar
[13]
disease risk: A systematic review and Google Scholar
[14]
meta-analysis, J Res Med Sci, 21, 2016, pp. 12. Google Scholar
[15]
Linder R, Rönmark E et al., Serum metalloproteinase-9 Google Scholar
[16]
is related to COPD severity and symptoms - cross- Google Scholar
[17]
sectional data from a population based cohort-study, Google Scholar
[18]
Respir Res, 16(1), 2015, pp.28. Google Scholar
[19]
The Global Initiative for Chronic Obstructive Google Scholar
[20]
Lung Disease, Global stragery for prevention, Google Scholar
[21]
diagnosis and management of COPD: 2023 Report, 2023. Google Scholar
[22]
Mahor D, Kumari V et al., Elevated serum matrix Google Scholar
[23]
metalloprotease (MMP-2) as a candidate Google Scholar
[24]
biomarker for stable COPD, BMC Pulm Med, Google Scholar
[25]
(1), 2020, pp. 302. Google Scholar
[26]
Russell RE, Culpitt SV et al., Release and activity Google Scholar
[27]
of matrix metalloproteinase-9 and tissue inhibitor of Google Scholar
[28]
metalloproteinase-1 by alveolar macrophages from Google Scholar
[29]
patients with chronic obstructive pulmonary disease, Google Scholar
[30]
Am J Respir Cell Mol Biol, 26(5), 2002, pp. 602-9. Google Scholar